Last reviewed · How we verify
R115777
R115777 is a Small molecule drug developed by SWOG Cancer Research Network. It is currently in Phase 2 development. Also known as: NSC-702818, Zarnestra, tipifarnib.
Tipifarnib, also known as R115777, is a farnesyltransferase inhibitor used in clinical trials for various types of cancer, including lung cancer, breast cancer, multiple myeloma, acute myeloid leukemia, and adult acute erythroid leukemia. It works by inhibiting the prenylation of the CAAX tail motif, which prevents the Ras protein from binding to the cell membrane and becoming active.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | R115777 |
|---|---|
| Also known as | NSC-702818, Zarnestra, tipifarnib |
| Sponsor | SWOG Cancer Research Network |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma (PHASE2)
- Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) (PHASE2)
- Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (PHASE1, PHASE2)
- Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial (PHASE2)
- Expanded Access to Tipifarnib
- Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS (PHASE2)
- Tipifarnib in Subjects With Myelodysplastic Syndromes (PHASE2)
- Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- R115777 CI brief — competitive landscape report
- R115777 updates RSS · CI watch RSS
- SWOG Cancer Research Network portfolio CI
Frequently asked questions about R115777
What is R115777?
Who makes R115777?
Is R115777 also known as anything else?
What development phase is R115777 in?
Related
- Manufacturer: SWOG Cancer Research Network — full pipeline
- Also known as: NSC-702818, Zarnestra, tipifarnib
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing